Mechanism of Action Differences
Both lacosamide and carbamazepine are voltage-gated sodium channel (VGSC) blockers, but lacosamide uniquely enhances slow inactivation of sodium channels while carbamazepine primarily affects fast inactivation—a fundamental mechanistic distinction that translates to different clinical profiles 1, 2.
Carbamazepine's Mechanism
Carbamazepine blocks sodium channels when they are activated, reducing polysynaptic responses and blocking post-tetanic potentiation 3. It:
- Shifts steady-state fast inactivation curves in the hyperpolarizing direction
- Retards recovery from fast inactivation
- Produces frequency-dependent facilitation of block during repetitive firing
- Acts primarily during the fast inactivation state of the channel 1
The drug is metabolized to carbamazepine-10,11-epoxide (which has equipotent anticonvulsant activity), induces cytochrome P450 enzymes, and has a half-life that decreases from 25-65 hours initially to 12-17 hours with chronic dosing due to autoinduction 3.
Lacosamide's Mechanism
Lacosamide is the only analgesic/anticonvulsant drug that reduces VGSC availability by selective enhancement of slow inactivation without affecting fast inactivation gating 1. Specifically, it:
- Selectively enhances slow inactivation of voltage-gated sodium channels
- Shifts the slow inactivation voltage curve in the hyperpolarizing direction
- Promotes entry of channels into the slow inactivated state
- Does NOT alter the voltage-dependence of activation
- Does NOT shift steady-state fast inactivation curves
- Does NOT retard recovery from fast inactivation
- Does NOT produce frequency-dependent block during repetitive firing 1, 2
This selective action on slow inactivation may be particularly effective for repeatedly depolarized neurons participating in seizure activity, where persistence of sodium currents is more pronounced 2.
Effect on Absolute Refractory Period
The absolute refractory period is determined by the time required for sodium channels to recover from inactivation:
Carbamazepine prolongs the absolute refractory period by enhancing fast inactivation and retarding recovery from fast inactivation 1. This means neurons require more time before they can fire another action potential.
Lacosamide's effect on the absolute refractory period is indirect and mechanistically distinct—by enhancing slow inactivation without affecting fast inactivation or recovery kinetics, it preferentially reduces availability of sodium channels during sustained depolarizations rather than prolonging the classical absolute refractory period 1, 2. The drug facilitates slow inactivation both in terms of kinetics and voltage dependency, which may be relatively selective for repeatedly depolarized neurons 2.
Clinical Implications
Tolerability Profile
Lacosamide demonstrates lower incidence of arousal-related adverse events compared to carbamazepine 4. In neurocognitive testing:
- Carbamazepine: Statistically significant worsening of arousal function, sensory-perceptual functions, and cognitive functions 4
- Lacosamide: No statistically significant difference in sensory-perceptual functions; arousal and cognitive function data limited 4
Drug Interactions
Carbamazepine induces cytochrome P450, leading to multiple drug interactions and decreased blood levels over days of administration 4, 3. Lacosamide lacks this enzyme induction property 5, 6.
Efficacy Comparison
In trigeminal neuralgia, carbamazepine remains first-line with 70% of patients showing partial or complete pain relief 7. Lacosamide achieved pain relief in 66% of refractory TN cases after first-line treatment failure 8.
For epilepsy, both demonstrate efficacy in focal seizures, with lacosamide showing non-inferiority to controlled-release carbamazepine with better tolerability 9. Abruptly switching from carbamazepine to lacosamide may be safe and effective without cross-titration in controlled patients 9.
Safety Considerations
Carbamazepine carries higher risk of serious idiosyncratic reactions including life-threatening skin reactions (particularly in patients of Asian descent requiring genetic testing), bone marrow suppression, and hepatotoxicity 3. Lacosamide's main concerns include dose-related PR interval prolongation and lower risk of serious adverse effects 10, 6.
The therapeutic range for lacosamide (10-20 mg/L) may be too high—adjusting the upper limit to 12 mg/L is suggested to decrease toxicity while maintaining efficacy 11.